■Company Name

Post Genome Institute Co., Ltd.

■Company Address

6F Hongo Ishiwata Bldg., 3-38-1 Hongo, Bunkyo-ku, Tokyo 113-0033, JAPAN Tel: +81-3-5804-0371

Fax:+81-3-5804-0393

■Homepage Address

http://www.postgenome.jp/english/

■Email Contact

info@postgenome.jp

■President

■Principal Area of Business

Post Genome Institute Co., Ltd. (PGI) is a biotechnology venture company that carries out basic research and technology development to uncover the cause of diseases and establish basic platform technology for drug discovery

■Principal Products/Business Activities

l        Manufacture & Sales of Puresystem Kits- PGI provides our novel “reconstituted” in vitro transcription/translation technology, Puresystem technology, in kit forms.

l         Research & Development of Puresystem Technology- PGI actively continues the research and development of Puresystem technology and reflect this in the development and application of new Puresystem related products.

l        Customized Production & Purification of Proteins- Using puresystem, PGI manufactures proteins upon customer’s requests.

l        The IniTIA technology-PGI will announce soon its proprietary IniTIA (initial mRNA tag identification analysis) technology designed for comprehensive and quantitative analysis of transcription initiation sites of expressed mRNA. This cutting edge IniTIA technology can be used for various applications such as identifying and targeting disease-specific transcription variants or alternative splicing forms, and analyzing tumor-specific transcription.

l        Vaccine development- PGI is developing SARS (severe acute respiratory syndrome) vaccine with PURESYSTEM

l        Research & Development- PGI continues to explore and develop new areas in the post genomic research field by actively leading joint research projects with other pharmaceuticals companies,

■Business Goals

1) To Contribute to the Development, Manufacture, and Sales of High-Quality Pharmaceutical Products. We aim to achieve this through world-wide expansion of our outstanding Technology and Promotion of Genomic and Proteomic Research essential in Medical research and Drug Discovery .

2) To Activate Bio-Business and ultimately, the whole Industry. We aim to achieve this by eliciting new biotechnology seeds from Universities through constant communication with researchers, and to assist in the Commercialization of the new technologies on a timely basis .

■Year of Establishment

June 1 , 2000

■Company Photo